Grafa News and Videos — Page 813

Ceragon Networks (NASDAQ:CRNT) reported first-quarter revenue that surpassed analyst expectations, driven by resilient deployments of its millimeter-wave backhaul solutions across India and North America despite a slight year-over-year contraction in total sales.

Antalpha Platform Holding ((NASDAQ:ANTA) reported a 52% increase in first-quarter revenue, hitting the lower bound of its internal forecast as expansion into tokenized gold strategies cushioned a slight cooling in Bitcoin-collateralized loan deployment.

Driven Brands Holdings (NASDAQ:DRVN) reported a significant turnaround in its fourth-quarter bottom-line results, shaking off a prior-year net loss to deliver stable adjusted earnings supported by an expanded global automotive services retail footprint.

BioLineRx (NASDAQ:BLRX) and Hemispherian AS announced encouraging preclinical data for their oncology candidate GLIX1, showcasing the experimental drug’s potential to combat glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.

ECARX Holdings (NASDAQ:ECX) reported a 22% decline in first-quarter revenue as vehicle launch timelines shifted, though sweeping operational cost reductions allowed the automotive intelligence developer to narrow its losses and post positive adjusted EBITDA.

RADCOM (NASDAQ:RDCM) reported a 12% increase in first-quarter revenue and expanding profit margins, though the strong financial results were paired with the sudden resignation of five board directors on the eve of a highly contested shareholder showdown.

Eagle Materials (NYSE:EXP) reported record-high revenues for both the fourth quarter and full fiscal year 2026, driven by resilient pricing across its cement and wallboard segments, even as inflationary pressures trimmed net margins.

Thermon Group Holdings (NYSE:THR) reported record revenue for fiscal year 2026, driven by robust industrial process heating demand, even as one-time transaction costs tied to its upcoming merger temporarily compressed bottom-line profits.

Boston Scientific (NYSE:BSX) announced that the pivotal clinical trial for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy (IVL) Catheter met its primary safety and effectiveness endpoints, clearing a major hurdle for regulatory submission.

Canaan (NASDAQ:CAN): reported first-quarter revenue in line with its previously issued guidance, anchored by an expansion of its self-mining operations and strategic infrastructure acquisitions despite a challenging environment for hardware sales.